Showing results (11-20 of 14) with videos related to
Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
The Lancet. Haematology|December 22, 2015
Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trialJun Imagawa, Hideo Tanaka, Masaya Okada, et al.The Lancet. Haematology|January 25, 2020
Treatment-free remission after first-line dasatinib discontinuation in patients with chronic myeloid leukaemia (first-line DADI trial): a single-arm, multicentre, phase 2 trialShinya Kimura, Jun Imagawa, Kazunori Murai, et al.The Lancet. Haematology|November 26, 2021
Low-dose dasatinib in older patients with chronic myeloid leukaemia in chronic phase (DAVLEC): a single-arm, multicentre, phase 2 trialKazunori Murai, Hiroshi Ureshino, Takashi Kumagai, et al.Clinical Lymphoma, Myeloma & Leukemia|April 4, 2018
Final 3-year Results of the Dasatinib Discontinuation Trial in Patients With Chronic Myeloid Leukemia Who Received Dasatinib as a Second-line TreatmentMasaya Okada, Jun Imagawa, Hideo Tanaka, et al.Pageof 2